AAM
RXRX icon

Azzad Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Azzad Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.9K Buy
17,236
+2,828
+20% +$10.9K 0.01% 328
2025
Q4 		$58.9K Sell
14,408
-408
-3% -$2.02K 0.01% 327
2025
Q3 		$72.3K Sell
14,816
-1,252
-8% -$6.58K 0.01% 322
2025
Q2 		$81.3K Sell
16,068
-743
-4% -$3.65K 0.01% 307
2025
Q1 		$88.9K Buy
16,811
+2,982
+22% +$21.7K 0.01% 298
2024
Q4 		$93.5K Sell
13,829
-1,168
-8% -$7.85K 0.02% 169
2024
Q3 		$98.8K Sell
14,997
-828
-5% -$5.94K 0.01% 301
2024
Q2 		$119K Sell
15,825
-367
-2% -$3.2K 0.01% 292
2024
Q1 		$161K Buy
+16,192
New +$180K 0.02% 295

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Azzad Asset Management's RXRX Position: Q1 2026 in Review

Azzad Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 20% in Q1 2026, buying an estimated $10.9K and bringing the position to 17,236 shares worth $52.9K. The position accounts for 0.01% of the portfolio, ranked #328.

Azzad Asset Management first reported a position in RXRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $161K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Azzad Asset Management held 17,236 shares of Recursion Pharmaceuticals worth $52.9K as of Q1 2026.
  • Azzad Asset Management bought 2,828 Recursion Pharmaceuticals shares in Q1 2026, an estimated $10.9K.
  • Recursion Pharmaceuticals made up 0.01% of Azzad Asset Management's portfolio in Q1 2026, its #328 holding.
  • Azzad Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Azzad Asset Management's Recursion Pharmaceuticals position peaked at $161K in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Azzad Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.